British Columbia Medical Assistance in Dying Prescription

Size: px
Start display at page:

Download "British Columbia Medical Assistance in Dying Prescription"

Transcription

1 British Columbia Medical Assistance in Dying Prescription Date: Page 1 of 6 Upon completion of MAID: 1) to provide copy of MAR to Pharmacist for reconciling the return of unused and partially used medications in Prescription Accountability section of Prescription; 2) Pharmacist to provide copy of completed Prescription (including Prescription Accountability section) to ; 3) to fax completed Prescription (all sections, including MAR) with all other MAID forms to BC Coroners Service, Attention Deputy Chief Coroner, fax ; 4) For cases involving a health authority (HA), to fax or mail an additional copy of Prescription (all sections) to applicable HA (see bottom of page 4 for HA fax numbers and mailing information); 5) to retain a copy of Prescription (all sections) in patient s health record. Identification and Declaration Patient Information Name: Address: Medical Information (pertinent to medical assistance in dying - allergies, etc.): Medical / Nurse Practitioner Information () Name: CPSID #: CRNBC #: Address: Telephone Number: Signature: Medical / Nurse Practitioner Declaration () The will initial each statement to declare it is true. The Pharmacist will initial the first statement to acknowledge discussion and confirmation with. The intention is NOT that the Pharmacist performs an assessment of the patient s eligibility criteria or obtains consent from the patient these functions are to only be performed by the. I confirm the medications prescribed on this form are intended for the purpose of medical assistance in dying, and patient s drug therapy has been discussed. I have determined the patient is capable to consent to medical assistance in dying. I have determined the patient is suffering from a grievous and irremediable medical condition and meets the eligibility criteria. I have received informed consent from the patient authorizing medical assistance in dying. Name of other Medical / Nurse Practitioner who confirms that the patient meets the eligibility criteria. Pharmacist

2 Intravenous Protocol Administered by Medical / Nurse Practitioner Patient Name: Page 2 of 6 The following are the components of the Medical or Nurse Practitioner-Administered medical assistance in dying intravenous drug protocol. Initial to confirm the selected drug for each protocol component. Sign the form at the bottom to prescribe the selected medications. Indicate by checkmark whether IV Regimen is: midazolam (1 mg/ml) Local Anaesthetic lidocaine (20 mg/ml) Primary IV Kit x 2 (Pharmacist must dispense 2 identical IV kits of all drugs in a sealed / tamperproof container.) or Back-up IV Kit for Oral Regimen Dispensed Quantity Dosage Notes (Mitte) Anxiolytic (Initial to confirm anxiolytic is being ordered.) 10 mg x mg to 10 mg IV over 2 minutes. May repeat additional dose x 1 PRN. midazolam 1 mg/ml is preferred formulation. 40 mg 40 mg IV over 30 seconds. lidocaine 20 mg/ml is preferred formulation. COMA Inducing Agent (CHOOSE one of the two alternatives. Initial to indicate selected agent.) propofol (10 mg/ml) phenobarbital (120 mg/ml) Neuromuscular Blocker rocuronium (10 mg/ml) OR IV Line Flush Solution sodium chloride 0.9% solution 1 g x 1 1 g IV over 5 minutes. May repeat additional dose x 1 PRN. 3 g x 1 sodium chloride 0.9% 10 ml x 3 for injection (for dilution) 3 g (dilute to 50 ml with sodium chloride 0.9%) IV over 5 minutes. May repeat additional dose x 1 PRN. 200 mg 200 mg by rapid IV injection. 1 st line agent Obtain additional PRN from back-up IV kit, if required. 2 nd line agent phenobarbital 120 mg/ml is preferred formulation. Confirm deep medically-induced coma before administration. 10 ml x 6 Flush IV line after each medication to ensure entire dose is given AND to. Medical / Nurse Practitioner Signature () My signature serves to prescribe the medications initialed above for this patient. Signature Date CPSID # or CRNBC #

3 Oral Protocol Self-Administered (Supervised by Medical / Nurse Practitioner) Patient Name: Page 3 of 6 The following are the components of the Self-Administered medical assistance in dying oral drug protocol. Initial to confirm the selected drug(s) for each protocol component. Sign the form at the bottom to prescribe the selected medications. For controlled prescription drugs (e.g. morphine), provide an additional prescription written on a duplicate prescription form and attach to this form. Dispensed Dosage Notes Quantity (Mitte) Gastric Motility / Anti-Emetic metoclopramide 20 mg (tablets) ondansetron 8 mg (tablet) haloperidol 5mg (5 mg/ml) 10 mg tablets x 2 20 mg (2 tablets) orally one hour prior to ingesting comainducing agent. 8 mg tablet x 1 8 mg (1 tablet) orally one hour prior to ingesting comainducing agent. 5 mg intravenous vials x 2 Anxiolytic (Initial to confirm anxiolytic is being ordered.) LORazepam 0.5 mg (sublingual tablets) 0.5 mg sublingual tablets x 8 5 mg subcutaneous or IV over 1 minute PRN for emesis during procedure. May repeat additional dose x 1 PRN. 0.5 mg to 2 mg (1 to 4 tablets) sublingually, 5 to 10 minutes prior to ingesting coma-inducing agent, if needed for anxiety. May repeat additional dose x 1 PRN. COMA Inducing Agent (Initial to confirm each ingredient is being ordered.) Powder Mixture: phenobarbital powder* 20 g Shake well. Ingest the entire prescription in less chloral hydrate powder* 20 g than 4 minutes. morphine sulphate powder** [Note: Omit morphine if patient has significant morphine allergy (i.e. anaphylaxis)] ORA-Plus / ORA-Sweet (50/50) or Distilled Water for feeding tube 3 g qs to 120 ml *Active ingredients required for coma induction. **Optional, depending on patient factors (e.g., adverse effects, tolerance). Stable for 72 hours. Use haloperidol 5 mg/ml intravenous formulation Patient to follow with a small amount of nonfat, non-carbonated drink. If compound is to be administered via PEG or NG tube, replace ORA- Plus /ORA Sweet with 120 ml of water. Flush feeding-tube with 60 to 90 ml of water after medication. Notes: 1) must complete the Intravenous Protocol section of the prescription form to prescribe the specific contents of the back-up IV kit. 2) Pharmacist must dispense 1 po kit plus 1 IV kit as backup in sealed / tamperproof container. The backup IV kit should include a second dispensed quantity of propofol or phenobarbital (i.e., total dispensed quantity of propofol 1 g x 2, or phenobarbital 3g x 2 ). Medical / Nurse Practitioner Signature () My signature serves to prescribe the medications initialed above for this patient. Signature Date CPSID # or CRNBC #

4 Page 4 of 6 Prescription Planning Patient Name: Planned Date and Time of Prescription Release and Return of Unused Medications Planned Release Date (YYYY/MM/DD): Planned Return Date (YYYY/MM/DD): Planned Release Time (00:00 am/pm): Planned Return Time (00:00 am/pm): Plan for Concluding Medical Assistance in Dying Process Procedures have been established for the return of any unused and partially used medication(s) within 48 hours to the Pharmacy for secure and timely disposal. Any Pharmacist within the dispensing pharmacy can receive back unused and partially used medications from the. Completed Prescription Accountability Medication Administration Record The has been instructed on how to complete the Medication Administration Record for medical assistance in dying medications. Dispensing Sign-Off Completed Printed Name Signature College ID Date Time Dispensed by: (Pharmacist) Received by: () CPBC License #: CPSID # / CRNBC #: Confirmation of photo ID of, if applicable: Completed Return of All Unused and Partially Used Medications to Pharmacist for Disposal The will return all unused and partially used medications to the pharmacy within 48 hours of the patient s death. The Pharmacist will reconcile and document the return of unused and partially used medication(s) below. Medication Name(s) Form Strength Quantity Printed Name Signature College ID Date Time Returned by: () Received by: (Pharmacist) CPSID # / CRNBC #: CPBC License #: Health Authority fax numbers for submission of forms: For mailing addresses of Health Authorities, FHA: Fax: NHA: Fax: VIHA: Fax: see Document Submission Checklist, HLTH IHA: Fax: VCHA: Fax: PHSA: Fax:

5 Page 5 of 6 Medication Administration Record (Provide copy of completed MAR to Pharmacist) Medical Assistance in Dying Intravenous Protocol (Administered by Medical / Nurse Practitioner) Date: Name of Patient: PHN: Name of Medical / Nurse Practitioner (): CPSID #: CRNBC #: Signature: : Dose Administered Time Given Anxiolytic midazolam 2.5 to 10 mg IV over 2 minutes Anesthetic lidocaine 40 mg IV over 30 seconds Coma-inducing Agent - Choose propofol OR phenobarbital propofol 1 g IV over 5 minutes phenobarbital 3 g (dilute to 50 ml with sodium chloride 0.9%) IV over 5 minutes Neuromuscular Blocker Confirm patient is in deep medically-induced coma* prior to administration rocuronium 200 mg by rapid IV injection * Deep medically-induced coma: No response to verbal stimuli, unable to rouse; serious depression of circulation, evidenced by weak pulse; serious depression of ventilation, evidenced by slow, shallow breathing; no protective reflexes, such as eyelash reflex.

6 Page 6 of 6 Medication Administration Record (Provide copy of completed MAR to Pharmacist) Medical Assistance in Dying Oral Protocol (Supervised by Medical / Nurse Practitioner) Date: Name of Patient: PHN: Name of Medical / Nurse Practitioner (): CPSID #: CRNBC #: Signature: : Dose Administered Time Given Anti-emetic (prior to procedure) metoclopramide 20 mg (10 mg tablets x 2) 1 hour prior to the coma-inducing agent ondansetron 8 mg (1 tablet) 1 hour prior to coma-inducing agent Anxiolytic LORazepam 0.5 mg sublingual tablets 0.5 to 2 mg (1 to 4 tablets), 5 to 10 minutes prior to coma-inducing agent, as needed for anxiety Coma-inducing Agent phenobarbital powder 20 g chloral hydrate powder 20 g morphine sulphate powder 3 g (cross-out morphine, if not given) ***Shake well. *** Ingest entire mixture in less than 4 minutes, followed by a glass of water or non-carbonated, non-fat liquid of patient s choice. For PEG or NG tube administration, flush feeding-tube with 60 to 90 ml of water after medication. Anti-emetic (during procedure) haloperidol 5 mg SUBCUT or IV over 1 minute as needed for emesis

Medical Assistance in Dying (MAID) Pharmacy Protocols Aug 16, 2016 Developed in partnership with:

Medical Assistance in Dying (MAID) Pharmacy Protocols Aug 16, 2016 Developed in partnership with: Medical Assistance in Dying (MAID) Pharmacy Protocols Aug 16, 2016 Developed in partnership with: The Alberta College of Pharmacists The Alberta College of Physicians and Surgeons Alberta Health 1 Table

More information

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS The benefits of prefilled syringes for palliative care from the hospital pharmacy service In

More information

Administration of Medication

Administration of Medication Administration of Medication Prescribed medications must arrive in a container with the original, unaltered prescription label attached. The label must display all legal information required for a pharmacist

More information

The Oral MAiD Option in Canada Part 2: Processes for Providing. Review and Recommendations

The Oral MAiD Option in Canada Part 2: Processes for Providing. Review and Recommendations The Oral MAiD Option in Canada Part 2: Processes for Providing Review and Recommendations Harty C, Chaput AJ, Buna D, Trouton K, & Naik VN A Canadian Association of MAiD Assessors and Providers (CAMAP)

More information

FREQUENTLY ASKED QUESTIONS PHARMACISTS

FREQUENTLY ASKED QUESTIONS PHARMACISTS FREQUENTLY ASKED QUESTIONS PHARMACISTS Q. Why did the College update standards for methadone maintenance treatment (MMT)? A. The College updated standards for MMT in collaboration with PharmaCare and other

More information

PPP 1. Continuation, modification, and discontinuation of a medication

PPP 1. Continuation, modification, and discontinuation of a medication PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The

More information

Policy Guide Injectable Hydromorphone Maintenance Treatment (2018)

Policy Guide Injectable Hydromorphone Maintenance Treatment (2018) Professional Practice Policy #67 Policy Guide Injectable Hydromorphone Maintenance Treatment (2018) P2 Injectable Hydromorphone Maintenance Treatment Policy Guide All pharmacy managers, staff pharmacists,

More information

Algorithms for Symptom Management. In End of Life Care

Algorithms for Symptom Management. In End of Life Care Algorithms for Symptom Management In End of Life Care The Use of Drugs Beyond Licence (off label) -The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK regulates the activity of the

More information

Care in the Last Days of Life

Care in the Last Days of Life Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient

More information

Sedation in Children

Sedation in Children CHILDREN S SERVICES Sedation in Children See text for full explanation and drug doses Patient for Sedation Appropriate staffing Resuscitation equipment available Monitoring equipment Patient suitability

More information

APIDRA (insulin glulisine) injection vial APIDRA SOLOSTAR (insulin glulisine) subcutaneous solution pen-injector

APIDRA (insulin glulisine) injection vial APIDRA SOLOSTAR (insulin glulisine) subcutaneous solution pen-injector APIDRA SOLOSTAR (insulin glulisine) subcutaneous solution pen-injector Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Managing Your Pain After Day Surgery

Managing Your Pain After Day Surgery Managing Your Pain After Day Surgery Information for patients and families UHN Read this information to learn why it s important to manage your pain how to control your pain when you get home side effects

More information

SEVERE ALLERGY/ANAPHYLAXIS ACTION PLAN & TREATMENT AUTHORIZATION Appendix F-4A

SEVERE ALLERGY/ANAPHYLAXIS ACTION PLAN & TREATMENT AUTHORIZATION Appendix F-4A PART I - TO BE COMPLETED BY PARENT Student Date of Birth Teacher/Grade Allergy Route of Exposure Contact Ingestion Weight lbs. Inhalation Sting Asthmatic Yes* No *Higher risk for severe reaction Parent

More information

Referral Forms for TYVASO and REMODULIN

Referral Forms for TYVASO and REMODULIN Referral Forms for TYVASO and REMODULIN HOW TO GET STARTED Tyvaso and Remodulin are available only through select Specialty Pharmacy Services (SPS) providers. Follow these 5 simple steps to complete each

More information

This document is to help guide the use of the provided GRH IV Iron Sucrose package. The documents included in the IV Iron Sucrose Package are:

This document is to help guide the use of the provided GRH IV Iron Sucrose package. The documents included in the IV Iron Sucrose Package are: This document is to help guide the use of the provided GRH IV Iron Sucrose package. The documents included in the IV Iron Sucrose Package are: 1. Adult Outpatient Iron Sucrose Order set (page 2 and 3)

More information

NHS Grampian Staff Guidance For The Management Of Hypomagnesaemia In Adults. Consultation Group: See Page 4. Review Date: June 2021

NHS Grampian Staff Guidance For The Management Of Hypomagnesaemia In Adults. Consultation Group: See Page 4. Review Date: June 2021 NHS...... Grampian NHS Grampian Staff Guidance For The Management Of Hypomagnesaemia In Adults Co-ordinators: Consultation Group: Approver:. Senior Medicines Information Pharmacist See Page 4 Medicine

More information

Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin

Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin Package leaflet: Information for the patient NEGABAN 1g, powder for solution for injection or infusion Temocillin Read all of this leaflet carefully before you start using this medicine because it contains

More information

Research Implementation Office (RIO) Solid Tumor/Heme/Heme Malignancy Protocol Specific Pre printed Order (PPO) Guidelines

Research Implementation Office (RIO) Solid Tumor/Heme/Heme Malignancy Protocol Specific Pre printed Order (PPO) Guidelines Research Implementation Office Solid Tumor/Heme/Heme Malignancy Protocol Specific Pre printed Order (PPO) Guidelines Note: As of February 11, 2015, the only preprinted orders which remain on paper for

More information

The only sublingual grass allergy immunotherapy tablet with a mixed pollens allergen extract from 5 grasses 1

The only sublingual grass allergy immunotherapy tablet with a mixed pollens allergen extract from 5 grasses 1 The only sublingual grass allergy immunotherapy tablet with a mixed pollens allergen extract from 5 grasses 1 An important immunotherapy option for patients with grass allergies Effective during the first

More information

Methadone/Buprenorphine Prescriptions

Methadone/Buprenorphine Prescriptions Methadone/Buprenorphine Prescriptions From office to pharmacy to patient Joy Bhimji BSP Methadone/Buprenorphine 101 Workshop December 10, 2016 Which prescription (Rx)? Suboxone write in DWI, carry info

More information

Medication Safety Presentation

Medication Safety Presentation Appendix E Aid 1: Sample Event Poster Medication Safety Presentation Do YOU know your role on the healthcare team? Do YOU know the questions to ask your pharmacist? Do YOU know safe medication practices?

More information

INFORMATION FOR FILLING OUT APPLICATION FORM FOR AN EXEMPTION TO USE A CONTROLLED SUBSTANCE FOR SCIENTIFIC PURPOSES (a Health Canada document)

INFORMATION FOR FILLING OUT APPLICATION FORM FOR AN EXEMPTION TO USE A CONTROLLED SUBSTANCE FOR SCIENTIFIC PURPOSES (a Health Canada document) INFORMATION FOR FILLING OUT APPLICATION FORM FOR AN EXEMPTION TO USE A CONTROLLED SUBSTANCE FOR SCIENTIFIC PURPOSES (a Health Canada document) Quote from Health Canada website: http://www.hc-sc.gc.ca/hc-ps/substancontrol/exemptions/index-eng.php

More information

Administration and Supply of Emergency Medicines

Administration and Supply of Emergency Medicines APPENDIX WHO CAN GIVE WHAT? Administration and Supply of Emergency Clinician Authorisation Key to Exemptions from legislation: NPP Non Parenteral POM. Can be given according to a protocol. 7 HMR 0, Schedule

More information

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice. Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative

More information

Contributes to CQC Outcome number: 9&12 Consulted With Post/Committee/Group Date. Pharmacist. Alison Felton Head of Pharmacy/Deputy Chief.

Contributes to CQC Outcome number: 9&12 Consulted With Post/Committee/Group Date. Pharmacist. Alison Felton Head of Pharmacy/Deputy Chief. Prescribing paracetamol in adult inpatients at MEHT Type: Clinical Guideline Register No: 18005 Status: Public on ratification Developed in response to: In line with Basildon Contributes to CQC Outcome

More information

CONTINUATION OF IMMUNOTHERAPY INJECTIONS AT RIDER UNIVERSITY ALLERGIST INFORMATION AND PERMISSION FORM

CONTINUATION OF IMMUNOTHERAPY INJECTIONS AT RIDER UNIVERSITY ALLERGIST INFORMATION AND PERMISSION FORM CONTINUATION OF IMMUNOTHERAPY INJECTIONS AT RIDER UNIVERSITY ALLERGIST INFORMATION AND PERMISSION FORM Dear Allergist: Your patient,, would like to continue allergy injections in our health center while

More information

Module 8: Practice Problems

Module 8: Practice Problems Module 8: Practice Problems 1. Convert a blood plasma level range of 5 to 20 µg/ml of tobramycin (Z = 467.52) to µmol/l. 5 µg/ml = 10.7 µmol/l 20 µg/ml = 42.8 µmol/l 2. A preparation contains in each milliliter,

More information

Attach patient label here. Physician Orders ADULT: Palliative Care Plan

Attach patient label here. Physician Orders ADULT: Palliative Care Plan Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase T;N, Phase: Palliative Care Phase, When to Initiate: Palliative Care Phase Admission/Transfer/Discharge Patient Status Initial

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Cisatracurium 2 mg/ml Solution for injection/ infusion Cisatracurium 5 mg/ml Solution for injection/ infusion Cisatracurium The name of your medicine are Cisatracurium

More information

Access to Palliative Care Drugs and Advice through Lothian Primary Care NHS Trust Community Pharmacy Palliative Care Network

Access to Palliative Care Drugs and Advice through Lothian Primary Care NHS Trust Community Pharmacy Palliative Care Network Access to Palliative Care Drugs and Advice through Lothian Primary Care NHS Trust Community Pharmacy Palliative Care Network Information for GPs, community pharmacists and district nurses First issued

More information

Midazolam Injection Midazolam

Midazolam Injection Midazolam Midazolam Injection Midazolam Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Midazolam Injection. It does not contain all the available information.

More information

Methadone 8.3. Dispensing (Ontario) This document describes the recommended way to setup and dispense Methadone mixtures.

Methadone 8.3. Dispensing (Ontario) This document describes the recommended way to setup and dispense Methadone mixtures. Methadone 8.3 Dispensing (Ontario) This document describes the recommended way to setup and dispense Methadone mixtures. Last Updated: February 15, 2010 Table of Contents Methadone Drug and Mixture Card

More information

IMPORTANT: PLEASE READ

IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION ALPROLIX [pronounced all prō liks] Coagulation Factor IX (Recombinant), Fc Fusion Protein This leaflet is part III of a three-part "Product Monograph" published when ALPROLIX

More information

PATIENT GROUP DIRECTION (PGD)

PATIENT GROUP DIRECTION (PGD) PATIENT GROUP DIRECTION (PGD) SUPPLY OF NALOXONE HYDROCHLORIDE INJECTION BY REGISTERED NURSES TO CLIENTS BEING RELEASED FROM HMP FORD Version Number: 01HMP Patient Group Direction originally drawn up by:

More information

Drug Prescription and Administration Record

Drug Prescription and Administration Record Chart No. this admission Drug Prescription and Administration Record Patient s Name: of Admission: Chart Start : Chart Finish : NHS No: Consultant Code: Ward: ALERT: of Birth: ADDITIONAL CAUTIONS FOR PRESCRIBING

More information

Hazardous Materials Medication Box and Exchange Procedure

Hazardous Materials Medication Box and Exchange Procedure September 2012 Page 1 of 6 Hazardous Materials Medication Box and Exchange Procedure EMS Service Stock 1. Each EMS Agency will be responsible for the security and storage of the supply of hazardous material

More information

Hazardous Materials Medication Box and Exchange Procedure

Hazardous Materials Medication Box and Exchange Procedure May 2017 Page 1 of 5 Hazardous Materials Medication Box and Exchange Procedure EMS Service Stock 1. Each EMS Agency will be responsible for the security and storage of the supply of hazardous material

More information

Sedation in children and young people. Appendix J. Sedation for diagnostic and therapeutic procedures in children and young people

Sedation in children and young people. Appendix J. Sedation for diagnostic and therapeutic procedures in children and young people SEDATION IN CHILDREN AND YOUNG PEOPLE 1 Sedation in children and young people Sedation for diagnostic and therapeutic procedures in children and young people Appendix J 2 SEDATION IN CHILDREN AND YOUNG

More information

User Guide for Transition to the Drug Information System

User Guide for Transition to the Drug Information System User Guide for Transition to the Drug Information System Document Revision History Date Description Version Updated By August 12, 2013 New/revised content 1.0 Lori Emery Version 1.0 Page 2 of 13 Table

More information

Opioids in the Community: Chronic pain, Palliative Care, and Addiction. Dr Ahmed Jakda September 2017

Opioids in the Community: Chronic pain, Palliative Care, and Addiction. Dr Ahmed Jakda September 2017 Opioids in the Community: Chronic pain, Palliative Care, and Addiction Dr Ahmed Jakda September 2017 Outline Context Background Action Delisting Highstrength Long- Acting Opioids Opioid use and prescribing

More information

Intravenous Immunoglobulin (IVIg) prescribing guidance

Intravenous Immunoglobulin (IVIg) prescribing guidance Intravenous Immunoglobulin (IVIg) prescribing guidance Kejal Mehta (Specialist Pharmacist) [December 2016] Review Date: December 2017 Contents Introduction:... 2 Prior to Intravenous immunoglobulin (IVIg)

More information

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure. Care of the Dying Early diagnosis of the dying process allows for adequate preparation of the patient, the family and the carers. This clinical guidance covers the prescribing and management of patients

More information

Help Prevent Medication Errors with PDC Healthcare s Anesthesia Labels & Tapes

Help Prevent Medication Errors with PDC Healthcare s Anesthesia Labels & Tapes Help Prevent Medication Errors with PDC Healthcare s Anesthesia Labels & Tapes Where positive identification meets safe, efficient patient care. Improve Patient Safety with Accurate Medication Labeling

More information

LEVEMIR (insulin detemir) subcutaneous solution LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector

LEVEMIR (insulin detemir) subcutaneous solution LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

Read all of this leaflet carefully before you are given this medicine because it contains important information for you. [Aspen] Package Leaflet: Information for the Patient Ultiva for injection remifentanil hydrochloride Read all of this leaflet carefully before you are given this medicine because it contains important

More information

Ketorolac injection. Supportive care

Ketorolac injection. Supportive care Supportive care Ketorolac injection Supportive care: specialist medicines This leaflet provides information on a medicine called ketorolac which is used to treat pain that is difficult to control. It is

More information

Package Leaflet: Information for the User Zotron 4mg/2ml (ή 8mg/4ml) Solution for Injection or Infusion ondansetron

Package Leaflet: Information for the User Zotron 4mg/2ml (ή 8mg/4ml) Solution for Injection or Infusion ondansetron Package Leaflet: Information for the User Zotron 4mg/2ml (ή 8mg/4ml) Solution for Injection or Infusion ondansetron Read all of this leaflet carefully before you start taking this medicine because it contains

More information

Compounding KI for Radiation Exposure

Compounding KI for Radiation Exposure PL Detail-Document #270323 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2011 Compounding KI for

More information

ADULT Updated: September 4, 2018

ADULT Updated: September 4, 2018 Updated: September 4, 2018 Regimen Reference Order ARIA: LYMP [R-CHOP alt. R-DHAP] Planned Course: Indication for Use: Every 21 days for 6 cycles (R-CHOP given on cycles 1, 3 and 5; R-DHAP given on cycles

More information

Administering Medicines to Students Asthma Inhaler Exemption

Administering Medicines to Students Asthma Inhaler Exemption Administering Medicines to Students Asthma Inhaler Exemption Any school employee authorized in writing by the district administrator or school principal: 1. May assist in the self-administration of any

More information

PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain

PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain Index No: MMG43 PAEDIATRIC DOSAGE GUIDELINES For management of post-operative acute pain Version: 3.1 (Includes anti-emetics and naloxone) Date ratified: July 2013 Ratified by: (Name of Committee) Name

More information

Controlled Drugs Accountable Officers Network Scotland Executive Group. Gabapentin and Pregabalin - Frequently Asked Questions

Controlled Drugs Accountable Officers Network Scotland Executive Group. Gabapentin and Pregabalin - Frequently Asked Questions Gabapentin and Pregabalin - Frequently Asked Questions Gabapentin and pregabalin will become Schedule 3 Controlled Drugs in April 2019 NHS Contractor Services Prescribers are legally permitted to be in

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cisatracurium 2 mg/ml solution for injection/infusion Cisatracurium 5 mg/ml solution for injection/infusion

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cisatracurium 2 mg/ml solution for injection/infusion Cisatracurium 5 mg/ml solution for injection/infusion PACKAGE LEAFLET: INFORMATION FOR THE USER Cisatracurium 2 mg/ml solution for injection/infusion Cisatracurium 5 mg/ml solution for injection/infusion Cisatracurium Read all of this leaflet carefully before

More information

Regulations: Adult Minimal Sedation

Regulations: Adult Minimal Sedation Regulations: Adult Minimal Sedation Jason H. Goodchild, DMD DrGoodchild@yahoo.com April 2017 Regulations Caveats 1. The regulations about to be presented are accurate and current as of today. 2. This could

More information

A step-by-step preparation guide

A step-by-step preparation guide A step-by-step preparation guide For needle and needle-free systems This guide provides detailed instructions on the reconstitution, dilution, and storage of VELETRI. It is intended to be used after your

More information

Dispensing and administration of emergency opioid antagonist without a

Dispensing and administration of emergency opioid antagonist without a 68-7-23. Dispensing and administration of emergency opioid antagonist without a prescription. (a) A pharmacist may dispense an FDA-approved emergency opioid antagonist and the necessary medical supplies

More information

BC OPIOID SUBSTITUTION TREATMENT SYSTEM Performance Measures 2012/2013

BC OPIOID SUBSTITUTION TREATMENT SYSTEM Performance Measures 2012/2013 BC OPIOID SUBSTITUTION TREATMENT SYSTEM Performance Measures 212/213 Office of the Provincial Health Officer With contributions by: Medical Beneficiary & Pharmaceutical Services Division & Population and

More information

Safe Medication Use. Patient Teaching Slides

Safe Medication Use. Patient Teaching Slides Safe Medication Use Patient Teaching Slides 3 Ways to Improve Medication Safety 1. Talk to your Doctor or Pharmacist about Your Medications 2. Organize, Store, Secure, and Dispose of Your Medications Safely

More information

IMPORTANT: PLEASE READ

IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION ALPROLIX [pronounced all prō liks] Coagulation Factor IX (Recombinant), Fc Fusion Protein This leaflet is part III of a three-part "Product Monograph" published when ALPROLIX

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Lartruvo 10 mg/ml concentrate for solution for infusion olaratumab This medicine is subject to additional monitoring. This will allow quick identification of new

More information

Evidence-Based Clinical Practice Guideline. Treatment & Management of Ocular Disease

Evidence-Based Clinical Practice Guideline. Treatment & Management of Ocular Disease Evidence-Based Clinical Practice Guideline Treatment & Management of Ocular Disease Effective November 29, 2017 Treatment & Management Of Ocular Disease Clinical Practice Guideline The objective of this

More information

Unit 204 Assist with the assembly of prescribed items

Unit 204 Assist with the assembly of prescribed items Element 1 Assemble prescribed 171 172 Element 1 Assemble prescribed Background Assembling prescribed is a complex process. The two main components of this process are labelling and dispensing. It is essential

More information

Naloxone and Combating the Opioid Epidemic

Naloxone and Combating the Opioid Epidemic Objectives Naloxone and Combating the Opioid Epidemic Jeff Jacobson PharmD Southpointe Pharmacy Discuss the current opioid crisis Define the role of Naloxone in opioid overdose Analyze the barriers to

More information

MIDAZOLAM APOTEX Solution for Injection Contains the active ingredient midazolam

MIDAZOLAM APOTEX Solution for Injection Contains the active ingredient midazolam MIDAZOLAM APOTEX Solution for Injection Contains the active ingredient midazolam Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet Read this leaflet

More information

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance

More information

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical

More information

PHYSICIAN ORDER SET : Patient: DOB: Gender: Patient Phone #: Height: Weight:

PHYSICIAN ORDER SET : Patient: DOB: Gender: Patient Phone #: Height: Weight: . (Patient Sticker) CDH 208-203 Approved 2/18 - Page 1 of 5 Patient: DOB: Gender: Patient Phone #: Height: Weight: Diagnosis: ICD-10 Code: Treatment Start Date: Provider Facility Name: Ordering Provider:

More information

CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY

CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY CHEMOTHERAPY NETWORK GROUP POLICY FOR ADMINISTRATION OF CYTOTOXIC CHEMOTHERAPY Version 4.0 March 2016 Review date March 2018 Introduction It is the purpose of this policy to provide clear guidelines that

More information

DUKORAL. Oral inactivated cholera and ETEC vaccine. Consumer Medicine Information. It does not take the place of talking to your doctor or pharmacist.

DUKORAL. Oral inactivated cholera and ETEC vaccine. Consumer Medicine Information. It does not take the place of talking to your doctor or pharmacist. What is in this leaflet DUKORAL Oral inactivated cholera and ETEC vaccine Consumer Medicine Information This leaflet answers some common questions about Dukoral. It does not contain all the available information.

More information

Medication Safety. Patient Safety. Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016

Medication Safety. Patient Safety. Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016 Medication Safety Patient Safety Setting Direction Julie Simmons, Medication Safety Pharmacist January 2016 1 The patient journey Admission Ward Transfer Ward stay Discharge Medication storage and supply

More information

Artesunate 60 mg for injection WHOPAR part 3 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET

Artesunate 60 mg for injection WHOPAR part 3 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET PATIENT INFORMATION LEAFLET 1 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Artesun * Artesunate 60 mg for injection and sodium bicarbonate injection 50 mg/ml (1ml) and sodium chloride injection

More information

Nova Scotia Drug Information System

Nova Scotia Drug Information System Nova Scotia Drug Information System Functions Presentation Details: Slides: 19 Duration: 00:32:04 Filename: DIS Module4.Functions.ppt Presenter Details: Slide 1 Nova Scotia Drug Information System Duration:

More information

For further copies of this leaflet, visit emc.medicines.org.uk or call Aspen on +44 (0) Package leaflet: Information for the user

For further copies of this leaflet, visit emc.medicines.org.uk or call Aspen on +44 (0) Package leaflet: Information for the user For further copies of this leaflet, visit emc.medicines.org.uk or call Aspen on +44 (0)1 748 828 391. Package leaflet: Information for the user Diprivan 10 mg/ml (1%) Emulsion for Injection or Infusion

More information

Appendix 3: Taking controlled and prescription drugs to other countries

Appendix 3: Taking controlled and prescription drugs to other countries Appendix 3: Taking controlled and prescription drugs to other countries Some patients receiving palliative care travel to other countries and they will need to take their medicines with them. Practitioners

More information

SECTION PRESCRIPTIONS

SECTION PRESCRIPTIONS SECTION.1800 - PRESCRIPTIONS 21 NCAC 46.1801 EXERCISE OF PROFESSIONAL JUDGMENT IN FILLING PRESCRIPTIONS (a) A pharmacist or device and medical equipment dispenser shall have a right to refuse to fill or

More information

Introduction. Guidelines for patient involvement in the administration of insulin under supervision in hospital (Adult patients)

Introduction. Guidelines for patient involvement in the administration of insulin under supervision in hospital (Adult patients) Guidelines for patient involvement in the administration of insulin under supervision in hospital (Adult patients) Introduction This guideline is designed to provide a framework for patients to administer

More information

Naloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no

Naloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no THE SOUTH CAROLINA BOARD OF MEDICAL EXAMINERS AND THE SOUTH CAROLINA BOARD OF PHARMACY S JOINT PROTOCOL TO INITIATE DISPENSING OF NALOXONE HCI WITHOUT A PRESCRIPTION This joint protocol authorizes any

More information

Controlled Substance Prescribing: A Physician s Guide. Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System

Controlled Substance Prescribing: A Physician s Guide. Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System Controlled Substance Prescribing: A Physician s Guide Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System Objectives Review schedules of controlled substances and their propensity for

More information

Good Practice Guidance on Covert Administration of Medication

Good Practice Guidance on Covert Administration of Medication Good Practice Guidance on Covert Administration of Medication This good practice guidance is intended to be used as a framework for care home managers and domiciliary care providers in drawing up their

More information

Pain & Sedation Management in PICU. Marut Chantra, M.D.

Pain & Sedation Management in PICU. Marut Chantra, M.D. Pain & Sedation Management in PICU Marut Chantra, M.D. Pain Diseases Trauma Procedures Rogers Textbook of Pediatric Intensive Care, 5 th ed, 2015 Emotional Distress Separation from parents Unfamiliar

More information

Dear Parent or Guardian,

Dear Parent or Guardian, Dear Parent or Guardian, This summer may be a period of transition for you and your child. For a lot of our students it may even be the first time they are taking the lead in their personal care, including

More information

SYRINGE DRIVER MEDICATIONS

SYRINGE DRIVER MEDICATIONS SYRINGE DRIVER MEDICATIONS Christine Hull & Anita Webb Staff Nurses, Hospice in the Home 2015 Analgesics:- Groups of Medication used in Syringe Drivers Morphine sulphate Diamorphine Oxycodone Alfentanil

More information

2. Receive the Guidelines for the Allergist letter which is to be given to the prescribing allergist physician.

2. Receive the Guidelines for the Allergist letter which is to be given to the prescribing allergist physician. POLICY: Name of Policy Allergy Immunotherapy Section Clinical Records and Health Information Date Effective January 20, 2005 Date Last Reviewed June 21, 2017 Responsible for Review UCF SHS Director Approved

More information

Home Care Services HomeMed MedEQUIP Michigan Visiting Care Michigan Visiting Nurses Wheelchair Seating Service PROCEDURE

Home Care Services HomeMed MedEQUIP Michigan Visiting Care Michigan Visiting Nurses Wheelchair Seating Service PROCEDURE UNIVERSITY OF MICHIGAN HOSPITALS AND HEALTH CENTERS UMHHC-HCS: 253.054 First Approved Date: 3/2010 Home Care Services HomeMed MedEQUIP Michigan Visiting Care Michigan Visiting Nurses Wheelchair Seating

More information

URGENT UPDATED ADVICE ON DOSAGE OF OSELTAMIVIR IN CHILDREN UNDER ONE YEAR OF AGE WITH SWINE FLU

URGENT UPDATED ADVICE ON DOSAGE OF OSELTAMIVIR IN CHILDREN UNDER ONE YEAR OF AGE WITH SWINE FLU Primary and Community Care Directorate Pharmacy Division T: 0131-244 2518 F: 0131-244 2375 E: bill.scott@scotland.gsi.gov.uk 25 September 2009 abcdefghijklmnopqrstu = 1. Medical Directors NHS Boards 2.

More information

Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014)

Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1. Key Points. Aripiprazole Long-Acting Injection (Abilify Maintena ) Guidelines for Prescribing and Administration (Version 3 August 2014) 1.1 Aripiprazole long acting injection (LAI) is licensed / indicated

More information

Agency 71. Kansas Dental Board (Authorized by K.S.A and (Authorized by K.S.A and

Agency 71. Kansas Dental Board (Authorized by K.S.A and (Authorized by K.S.A and Agency 71 Kansas Dental Board Articles 71-4. CONTINUING EDUCATION REQUIREMENTS. 71-5. SEDATIVE AND GENERAL ANAESTHESIA. 71-11. MISCELLANEOUS PROVISIONS. Article 4. CONTINUING EDUCATION REQUIREMENTS 71-4-1.

More information

Renal Palliative Care Last Days of Life

Renal Palliative Care Last Days of Life Renal Palliative Care Last Days of Life Introduction This guideline is an aid to clinical decision-making and good practice for patients with stage 4-5 chronic kidney disease (egfr

More information

BC OPIOID SUBSTITUTION TREATMENT SYSTEM Performance Measures 2014/ /2016

BC OPIOID SUBSTITUTION TREATMENT SYSTEM Performance Measures 2014/ /2016 BC OPIOID SUBSTITUTION TREATMENT SYSTEM Performance Measures 2014/2015-2015/2016 Office of the Provincial Health Officer With contributions by: Medical Beneficiary & Pharmaceutical Services Division &

More information

Guidance on Bulk Prescribing for Care Home Patients

Guidance on Bulk Prescribing for Care Home Patients Guidance on Bulk Prescribing for Care Home Patients Introduction Many patients in care homes taking medicines when required (PRN) can inevitably present problems for the prescriber in determining the quantity

More information

Paediatric Prescribing Pocket Guide September 2014 (Version 1)

Paediatric Prescribing Pocket Guide September 2014 (Version 1) PAGE 1 Paediatric Prescribing Pocket Guide September 2014 (Version 1) In children, the risk of medication errors is often exacerbated by the need for calculations to determine the dose. Prescribing errors

More information

Package leaflet: Information for the patient. ROBAXIN mg Film-coated tablets for oral use Methocarbamol. 100 Tablets

Package leaflet: Information for the patient. ROBAXIN mg Film-coated tablets for oral use Methocarbamol. 100 Tablets Package leaflet: Information for the patient ROBAXIN - 750 750 mg Film-coated tablets for oral use Methocarbamol 100 Tablets Dosage: 2 tablets to be swallowed 4 times a day or as directed by your doctor.

More information

1. A patient receives the wrong drug (ex. verified Amox 875 drug dispensed should have been Augmentin 875)

1. A patient receives the wrong drug (ex. verified Amox 875 drug dispensed should have been Augmentin 875) July 12, 2018 Topic: Errors and Omissions Medications errors are made everyday. It is the job of the Pharmacist to prevent these errors from occurring. The right drug to the right patient at the right

More information

1. What Octostim Nasal Spray is and what it is used for

1. What Octostim Nasal Spray is and what it is used for Package Leaflet: Information for the User Octostim 1.5 mg/ml Nasal Spray Desmopressin acetate Read all of this leaflet carefully before you start using this medicine because it contains important information

More information

UMC Health System Patient Label Here. PHYSICIAN ORDERS Diagnosis

UMC Health System Patient Label Here. PHYSICIAN ORDERS Diagnosis Diagnosis Weight Allergies Patient Care Vital Signs Per Unit Standards q12h q12h, Temperature Only - Every Shift and PRN Patient Activity Assist as Needed, Bed Position: As Tolerated, elevate to patient

More information

Chapter 2 is a general introduction to the drug administration

Chapter 2 is a general introduction to the drug administration Chapter 2 Safe and Accurate Drug Administration Chapter Overview Chapter 2 is a general introduction to the drug administration process. It introduces the student to the role of the person who administers

More information

PATIENT INFORMATION LEAFLET. MIDORYX (MIDAZOLAM INJECTION 5mg, 10mg BP)

PATIENT INFORMATION LEAFLET. MIDORYX (MIDAZOLAM INJECTION 5mg, 10mg BP) PATIENT INFORMATION LEAFLET MIDORYX (MIDAZOLAM INJECTION 5mg, 10mg BP) Read all of this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you

More information

Safe Prescribing of Drugs with Potential for Misuse/Diversion

Safe Prescribing of Drugs with Potential for Misuse/Diversion College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines

More information

Artesunate 60 mg for injection WHOPAR part 3 November 2015 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET

Artesunate 60 mg for injection WHOPAR part 3 November 2015 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET PATIENT INFORMATION LEAFLET 1 PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER Artesun 60mg * Artesunate 60 mg for injection and sodium bicarbonate injection 50 mg/ml (1ml) and sodium chloride injection

More information

Package leaflet: Information for the patient. Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 )

Package leaflet: Information for the patient. Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 ) Package leaflet: Information for the patient Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 ) Roche Read all of this leaflet carefully before you start

More information